Movers and SHAKERS
Dyadic International Inc. (DYAI)
Confidence in 2020 Outlook
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system. The company’s partnership portfolio with pharmaceutical and institutions includes Zapi Project, Israel Institute for Biological Research, Mitsubishi Tanabe Pharma, Sanofi-Aventis covering the production of a diverse range of biologics, such as monoclonal antibodies, bispecific and Fc-fusion proteins. Dyadic also established a sub-licensing agreement with an Australian based drug development and contract manufacturing firm, Luina Bio, to utilize C1 platform for the development and commercialization of biological products to prevent and treat animal diseases. Company’s C1 bioenergy business was sold to Dupond Industrial Biosciences (DuPont) for $75 mm in 2015 granting the company the rights to use C1 platform in biopharma applications.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Expanded research collaborations in Q4 2019. Dyadic expanded research collaboration with Zoonoses Anticipation and Preparedness Initiative (ZAPI) to express two additional proteins based on the preliminary results from animal studies. In addition, Dyadic entered into a new collaboration with a pharmaceutical company (in the top ten) expanding its portfolio to six proof of concept research collaborations. Lastly, a research license agreement was established with an affiliate of a current research collaborator (a top 25 pharmaceutical company) to further evaluate C1 technology with the objective of broadening and accelerating the adoption and use of C1 globally.
Presentations during the JPM healthcare conference. Dyadic’s management team continues to be proactive and open to meet with collaborators and investors. There will be few presentations by the management during JP Morgan including i) BFC Global Healthcare Investment Conference at 2:30 p.m. PST on January 12, Sunday, ii) China Focus at 10:50 a.m. PST on January 12, Sunday, and iii) Biotech Showcase at...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.